ITI Inc (NASDAQ:ITCI), a Company on the leading edge of transforming vaccines, announced the preliminary results of a Phase IB study of JRC-LAMP-vax™, a novel immunotherapy designed to treat individuals with allergy to Japanese red cedar (“JRC”). The Company is pleased to report that the Phase IB has met and maintained all primary safety and secondary immunological end points that were observed at the conclusion of the Phase IA. ITI Inc (NASDAQ:ITCI) stock performance was 11.27% in last session and finished the day at $18.36. Traded volume was 50.2K shares in the last session and the average volume of the stock remained 78.49K shares.
TherapeuticsMD, Inc. (NYSEMKT:TXMD) rose 300% since last fall, despite a lack of a legitimate, underlying fundamental reason. TherapeuticsMD Inc (NYSEMKT:TXMD) rose 6.48 percent to $4.93 Wednesday on volume of 1.93million shares. The intra-day range of the stock was $4.71 to $5.15. TherapeuticsMD Inc (NYSEMKT:TXMD) has a market capitalization of $715.18million.
KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) will present at the 13th Annual Needham Healthcare Conference at the Westin Grand Central Hotel in New York City, NY. The event is scheduled to begin at 11:20 AM ET on April 08,2014. KaloBios Pharmaceuticals Inc (NASDAQ:KBIO)’s stock on Apr 09, 2014 reported a increase of 2.89% to the closing price of $2.49. Its fifty two weeks range is $2.29 -$6.64. The total market capitalization recorded $82.12million. The overall volume in the last trading session was 265.1K shares. In its share capital, KBIO has 32.99million outstanding shares.
Auspex Pharmaceuticals, Inc. (NASDAQ:ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, announced that the Company was added to the Russell 2000® Index (as well as the larger Russell 3000 ® Index) at the close of market on March 31, 2014 as part of the quarterly Initial Public Offering (IPO) update to the Russell indexes. On Wednesday, shares of Auspex Pharmaceuticals Inc (NASDAQ:ASPX) advanced 7.83% to close the day at $32.38. Company monthly performance is recorded as 8.37%.